"One week Jun" 18 pharmaceutical companies among the Fortune China 500; anti-tumor drug shuffling; the United States to support Kodak to compete for raw materials, intended to bring back the pharmaceutical industry; Consinoco board to open the purchase;

Read: Kodak into the bureau "raw material medicine", Trump sword refers to the "pharmaceutical industry"! This week's look at 1. Anti-tumor drug shuffle! Focus on monitoring in key areas! 2.18 Pharmaceutical companies among the Fortune China 500! 3. Support Kodak to compete for apips? Intent to bring the pharmaceutical industry back to the United States 4. Consinoco's board to open the purchase of government news anti-tumor drug big shuffle! Focus on monitoring in key areas! On July 29, the National Health and Care Commission's Medical and Medical Hospital released the Measures for the Administration of Clinical Application of Anti-Tumor Drugs (draft for comments) (the "Draft for Comments"), which aims to further strengthen the management of the clinical application of anti-tumor drugs in medical institutions, improve the level of clinical rational application of anti-tumor drugs, standardize the clinical application behavior of anti-tumor drugs, and ensure medical quality and medical safety.
With the increase of cancer incidence in China, the reform of the drug regulatory review and approval system has further promoted the market of innovative drug research and development, and the cancer innovation drug has become a hot area of heavy investment of pharmaceutical companies.
around market segments and clinical needs, truly patient-centered, serious and rational use and benign market competition, has caused the regulatory authorities to attach great importance to.
content emphasizes "graded management" and "hyper-adaptive drug" strict supervision, on the one hand, with the future of innovative drugs continue to market, clinical use of more consideration is safety, accessibility and payment, really focus on clinical value.
on the other hand on the "hyperadaptive drug" emphasis in accordance with a certain level of evidence-based medical evidence for use and management. The third batch of national mining began, "light foot" enterprise turn-over machine July 29, Shanghai Sunshine Pharmaceutical Procurement Network issued "national organization of drug centralized procurement and use of the joint procurement office on the release of the "National Drug Centralized Procurement Document (GY-YD2020-1)" announcement (National Union of 2020 No. 1), while the network published the "procurement of varieties" "the first year of procurement of the first year of the agreement".
the number of enterprises with the largest number of finalists of the same variety in this procurement variety catalogue is determined according to the actual number of declared enterprises that meet the "declaration of variety qualification", up to 8.
analysts pointed out that the third batch of national procurement will continue to speed up the process of imitation substitution of original research.
for the larger varieties of stock sales, sales will shrink sharply after the collection due to a sharp drop in the winning bid price and a small increase in sales.
the high market share of enterprises even if the winning bid will be relatively large impact, especially the higher-priced original research enterprises;
therefore, for the large varieties of stock, the volume purchase has obvious reconstruction effect on its competitive pattern.
state health insurance administration: "New Crown" health insurance payment 1.2 billion July 28, the State Council policy briefing, the spokesman said that as of July 19, the country's new crown pneumonia confirmed and suspected patients have health insurance settlement of 1.355 million people, involving medical expenses of 1.847 billion yuan, health insurance payment of 1.232 billion yuan, the proportion of payment reached 67%.
ensure that patients are not affected by cost problems and that hospitaladmissions are not affected by payment policies.
to all confirmed and suspected patients to implement first treatment, after settlement, to assume the task of treatment of new crown pneumonia medical institutions to allocate special funds to ease the pressure of funds of medical institutions, and timely settlement with medical institutions.
this is a great power to assume, but also the national hope, it is also with this strong financial support, China can control the epidemic in such a short period of time, the world's most courageous anti-epidemic country.
the market hot smell 18 pharmaceutical companies into the Fortune China 500! On July 27th, the Fortune China 500 list was officially announced.
notable is the 18 pharmaceutical companies on the list.
among them, China Pharmaceutical Holdings, Shanghai Pharmaceuticals, China Resources Pharmaceuticals, Kyushu Tong a total of 4 pharmaceutical companies shortlisted within 100, and Guang medicine Baiyunshan, Yunnan White Medicine, Hengrui Pharmaceuticals, Shi Pharmaceutical Group, Renfu Pharmaceutical and other companies are also on the list.
list: China Pharmaceutical Holdings ranked 22nd on the list with revenues of 425.273 billion yuan, up three places from last year, making it the highest-earning and profitable pharmaceutical company on the list.
Kyushu Tong Pharmaceutical Group this year to improve 6 places, successfully into the top 100. of the 18 pharmaceutical companies that
to the list, 13 were ranked higher than last year, with Hengrui Pharmaceuticals rising the most from 470 last year to 393 this year;
it's worth noting that many of these companies are motivated by innovation.
a wide variety of important areas, thanks to its emphasis on research and development investment, innovation is their rapid growth, the basis of the list.
also confirmed that innovation is the key to china's pharmaceutical companies to win the future.
the top 20 best-selling drugs in the world in 2019, EvaluatePharma has released top 20 of the world's top 20 drug sales for 2019.
as EvaluatePharma predicted in early 2019, AbbVie's Humira, which has blocked many biosimilars until 2023 with tight patent protection, once again tops top of top 2019 top-selling drug companies, with $19.73 billion in sales that dropped nearly $10 billion.
's second tier behind Humira is a series of super anti-tumor drugs.
it's worth noting that PD-1 antibodies are two new players on the 2019 top-selling top 10 list.
Keytruda in Mershadon and Opdivo of BMS have left their rivals far behind with their clinical and approval success.
analysts say Mercado's huge advantage in lung cancer will help it become a new sales boss.
and the huge profits of innovative drugs have succeeded in focusing the global pharmaceutical community's attention on this.
corporate information to support Kodak to compete for apips? The U.S. government announced July 28 that it will provide Kodak with a $765 million loan to produce essential pharmaceutical ingredients defined by the FDA as a national shortage to promote the independence of its domestic drug production supply chain.
clearly, after the new crown outbreak, a battle for the API market has begun.
macro, China's advantage in the global pharmaceutical industry chain lies in the production and supply of upstream API, especially low-value-added bulk API, whose exports are close to 20% of the world's API market share.
India is China's largest export destination for API, accounting for 8% and 16.8% of China's API exports in 2019.
more than 60% of the raw materials used in its production are from China.
dependence on certain types of API, such as antibiotics, is close to 100%.
the U.S. move is "obvious" that Kodak has vast industrial facilities, including 16 million square feet of manufacturing space, laboratories, warehouses and offices, 88 mass-produced reactors, on-site power plants and steam supplies, and a long experience in organic chemical manufacturing.
after the new crown outbreak, if Kodak "api" smoothly, no doubt to a large extent to start the "global competition for API" the first shot, the characteristics of API is its "heavy weight." can
Trump's intention to use the "new crown" to bring the pharmaceutical industry back to the United States? Its heart is not small! Iodine sea alcohol api leading core plant explosion, listed companies emergency response on the evening of July 27, Shi Taili mainly produces iodine sea alcohol crude Xianju plant 3 workshop explosion, is now unable to normal production.
according to the latest announcement, the current Xianju plant has been in a state of self-inspection, the production time is not more than 3 months.
officials said that after the acceptance, the company will use the previous 3 workshops run in parallel 9 workshops to resume production, "should not have much impact on this year's overall production capacity."
" and will not carry out new material stakes until the government has completed the rectification and acceptance.
the current industry most of the first-line operators of the quality of secondary, high school, college level, and even a small number of junior high school operating workers, in dealing with emergency operations, lack of professional knowledge, the future is the Group to strengthen.
companies will also target the direction of environmental engineering, the recruitment of more professional background knowledge of the existing team to effectively upgrade.
lepp major business restructuring on the evening of July 29, Lepu Medical announced that the company intends to spin off its controlling subsidiary Beijing Lepu Diagnostics Technology Co., Ltd. ("Lepu Diagnostics") to the company's listing, the completion of the spin-off will not affect the control of subsidiary Lepu Diagnostics.
Lepu's main business is the development, production and sales of in vitro diagnostic reagents and instruments.
Lepu Medical said that the current company's in vitro diagnostic business scale is relatively low, after the spin-off listing, in vitro diagnostics sector has become an independent listed business sector, its business positioning is more clear.
enhances the profitability of Lepu Diagnostics by expanding the financing channels, enhancing the financial strength, and enhancing the research and development capabilities and the competitiveness of the industry by listing on the company's board.
The conshinoco board opened the purchase on July 31, Concino officially opened the purchase at Cotron Board, the issue price of 209.71 yuan per share.
Choice Financial Terminal data show that the issue price is the second-highest since the A-share issue, after the listing of stone technology (271.12 yuan per share) at the beginning of this year.
notable, Consino was successfully listed on the Main Board of the Stock Exchange of Hong Kong in March 2019, making it the first vaccine stock to be listed on the HkEx.
Kangsino was founded in 2009 by Four Marine Scientists, Dr. Yu Xuefeng, Dr. Zhu Tao, Dr. Qiu Dongxu and Dr. Mao Huihua.
more than a decade of development, the company has established four leading core technology platforms in vaccine development and production: polyglyprotein binding technology, protein structure design and recombination technology, adenovirus vector vaccine technology and formulation technology.
based on these technology platforms, the company has established a pipeline for the development of 16 innovative vaccine products for 13 disease areas, covering the prevention of a range of diseases such as new coronavirus pneumonia, Ebola virus disease, tuberculosis, meningitis, white-cut, shingles and herpes.
So far, Consino has a marketed product, the recombinant Ebola virus disease vaccine Ad5-EBOV, which was conditionally approved in China in October 2017.
the funds raised are intended for the expansion of new vaccine production capacity and the development of new vaccine products.
Amin's second-quarter results: Revenue growth of 6% profit fell 17% July 28, Anjin reported second quarter 2020 revenue of $6.2 billion, up 6% YoY, of which product sales were $5.9 billion, up 6%, and profit was $1.8 billion, down 17%.
, Aminhas reiterated its full-year revenue outlook, forecasting between $25-25.6 billion and raising its earnings per share forecast.
during the COVID-19 pandemic, the company's revenue growth was driven by a 13 percent increase in sales driven by the launch of several new drugs, including Otezla, which was purchased from new base in November 2019, as well as Mvasi, Kanjinti, Evenity and Repata.
but the impact of the outbreak, as well as intense competition for biosimilars and generics, are still relatively offset by a decline in sales of some drugs.
Microcore Bio: Revenue of 110 million yuan in the first half of 2020 increased 35% YoY July 27, Microcore Bio announced its first half 2020 results, operating income reached 110 million yuan, up 35% YoY;
announcement, the main reason for the increase in revenue for the current period was sales growth in its core product, Cidabenmine, and receipt of HUYA Technology Licensing Revenue.
as of the end of the reporting period, the cumulative sales of Sidabenamine exceeded 600 million yuan.
May 21, 2020, Sidabenamine completed the first phase of a phase III clinical trial of diffuse disphoin b cell lymphoma.
sources of information: Pharmaceutical Intelligence News, Sina Pharmaceutical News, Cypress Blue, E Pharmaceutical Manager, Pharmaceutical Economics, China Pharmaceutical News, Pharmacy Manager, Oriental Fortune Choice Data, E Company, Daily Economic News, Interface News, etc. Recommended reading: 1. "One week jun" three batches of countries to take the "bottom-up examination" to come; 2. "One week Jun" Junshi open market value of 150 billion, the use of "research and development" valuation; 3. 17 kinds of drugs "turned non-" in a week, three documents of the Drug Administration to help "breakthrough treatment ... 4. The new edition of the Chinese Pharmacopoeia affects the entire pharmaceutical industry; 5. "One-week Jun" DRG sub-group program under, pharmaceutical companies to plan ahead is the key! The...